English
简体中文
Total: £ 56.28
Published Date: 2026-03-27 | Pages: 129 | Tables: 136 | Pharma & Healthcare
The global Epidermal Growth Factor Receptor Inhibitors market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Epidermal Growth Factor Receptor Inhibitors competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Epidermal growth factor receptor inhibitors are a class of drugs used to treat diseases such as tumors. They act on the epidermal growth factor receptor (EGFR) and block the signaling pathway of this receptor, thereby inhibiting the growth, division and spread of tumor cells. EGFR is a membrane receptor tyrosine kinase that regulates cell growth and differentiation in normal cells. However, it is overexpressed or mutated in some tumor cells, leading to abnormal activation and thus promoting tumor development. Epidermal growth factor receptor inhibitors inhibit tumor growth and metastasis by binding to EGFR and blocking its activation. These drugs usually include small molecule tyrosine kinase inhibitors and monoclonal antibodies, which are widely used in the treatment of various malignant tumors such as lung cancer and colorectal cancer.
The North American market for Epidermal Growth Factor Receptor Inhibitors is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Epidermal Growth Factor Receptor Inhibitors is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Epidermal Growth Factor Receptor Inhibitors include AstraZeneca, Roche, Pfizer, Spectrum Pharmaceuticals, Cullinan Oncology, Taiho Pharmaceutical, Lutris Pharma, Boehringer Ingelheim, Puma Biotechnology, Apollomics, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Epidermal Growth Factor Receptor Inhibitors market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Epidermal Growth Factor Receptor Inhibitors. The Epidermal Growth Factor Receptor Inhibitors market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Epidermal Growth Factor Receptor Inhibitors market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Epidermal Growth Factor Receptor Inhibitors manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AstraZeneca
Roche
Pfizer
Spectrum Pharmaceuticals
Cullinan Oncology
Taiho Pharmaceutical
Lutris Pharma
Boehringer Ingelheim
Puma Biotechnology
Apollomics
Hutchison MediPharma
Johnson & Johnson Services
Daiichi Sankyo
Hutchison China MediTech
Sihuan Pharmaceutical
Astellas Pharma
Segment by Type
Cetuximab
Erlotinib
Gefitinib
Other
by Application
Lung Cancer
Liver Cancer
Breast Cancer
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Epidermal Growth Factor Receptor Inhibitors manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Epidermal Growth Factor Receptor Inhibitors sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Epidermal Growth Factor Receptor Inhibitors Market Overview
1.1 Product Definition
1.2 Epidermal Growth Factor Receptor Inhibitors by Type
1.2.1 Global Epidermal Growth Factor Receptor Inhibitors Market Value by Type: 2025 vs 2032
1.2.2 Cetuximab
1.2.3 Erlotinib
1.2.4 Gefitinib
1.2.5 Other
1.3 Epidermal Growth Factor Receptor Inhibitors by Application
1.3.1 Global Epidermal Growth Factor Receptor Inhibitors Market Value by Application: 2025 vs 2032
1.3.2 Lung Cancer
1.3.3 Liver Cancer
1.3.4 Breast Cancer
1.3.5 Other
1.4 Global Epidermal Growth Factor Receptor Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Epidermal Growth Factor Receptor Inhibitors Revenue 2021–2032
1.4.2 Global Epidermal Growth Factor Receptor Inhibitors Sales 2021–2032
1.4.3 Global Epidermal Growth Factor Receptor Inhibitors Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Epidermal Growth Factor Receptor Inhibitors Market Competition by Manufacturers
2.1 Global Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Manufacturers (2021–2026)
2.2 Global Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Epidermal Growth Factor Receptor Inhibitors Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Epidermal Growth Factor Receptor Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Epidermal Growth Factor Receptor Inhibitors, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Epidermal Growth Factor Receptor Inhibitors, Product Types and Applications
2.7 Global Key Manufacturers of Epidermal Growth Factor Receptor Inhibitors, Date of Entry into the Industry
2.8 Global Epidermal Growth Factor Receptor Inhibitors Market Competitive Situation and Trends
2.8.1 Global Epidermal Growth Factor Receptor Inhibitors Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Epidermal Growth Factor Receptor Inhibitors Players Market Share by Revenue
2.8.3 Global Epidermal Growth Factor Receptor Inhibitors Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Epidermal Growth Factor Receptor Inhibitors Market Scenario by Region
3.1 Global Epidermal Growth Factor Receptor Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Epidermal Growth Factor Receptor Inhibitors Sales by Region: 2021–2032
3.2.1 Global Epidermal Growth Factor Receptor Inhibitors Sales by Region: 2021–2026
3.2.2 Global Epidermal Growth Factor Receptor Inhibitors Sales by Region: 2027–2032
3.3 Global Epidermal Growth Factor Receptor Inhibitors Revenue by Region: 2021–2032
3.3.1 Global Epidermal Growth Factor Receptor Inhibitors Revenue by Region: 2021–2026
3.3.2 Global Epidermal Growth Factor Receptor Inhibitors Revenue by Region: 2027–2032
3.4 North America Epidermal Growth Factor Receptor Inhibitors Market Facts & Figures by Country
3.4.1 North America Epidermal Growth Factor Receptor Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Epidermal Growth Factor Receptor Inhibitors Sales by Country (2021–2032)
3.4.3 North America Epidermal Growth Factor Receptor Inhibitors Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Epidermal Growth Factor Receptor Inhibitors Market Facts & Figures by Country
3.5.1 Europe Epidermal Growth Factor Receptor Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Epidermal Growth Factor Receptor Inhibitors Sales by Country (2021–2032)
3.5.3 Europe Epidermal Growth Factor Receptor Inhibitors Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Epidermal Growth Factor Receptor Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Epidermal Growth Factor Receptor Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Epidermal Growth Factor Receptor Inhibitors Sales by Region (2021–2032)
3.6.3 Asia Pacific Epidermal Growth Factor Receptor Inhibitors Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Epidermal Growth Factor Receptor Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Epidermal Growth Factor Receptor Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Epidermal Growth Factor Receptor Inhibitors Sales by Country (2021–2032)
3.7.3 Latin America Epidermal Growth Factor Receptor Inhibitors Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Sales by Country (2021–2032)
3.8.3 Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Epidermal Growth Factor Receptor Inhibitors Sales by Type (2021–2032)
4.1.1 Global Epidermal Growth Factor Receptor Inhibitors Sales by Type (2021–2026)
4.1.2 Global Epidermal Growth Factor Receptor Inhibitors Sales by Type (2027–2032)
4.1.3 Global Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Type (2021–2032)
4.2 Global Epidermal Growth Factor Receptor Inhibitors Revenue by Type (2021–2032)
4.2.1 Global Epidermal Growth Factor Receptor Inhibitors Revenue by Type (2021–2026)
4.2.2 Global Epidermal Growth Factor Receptor Inhibitors Revenue by Type (2027–2032)
4.2.3 Global Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Type (2021–2032)
4.3 Global Epidermal Growth Factor Receptor Inhibitors Price by Type (2021–2032)
5 Segment by Application
5.1 Global Epidermal Growth Factor Receptor Inhibitors Sales by Application (2021–2032)
5.1.1 Global Epidermal Growth Factor Receptor Inhibitors Sales by Application (2021–2026)
5.1.2 Global Epidermal Growth Factor Receptor Inhibitors Sales by Application (2027–2032)
5.1.3 Global Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Application (2021–2032)
5.2 Global Epidermal Growth Factor Receptor Inhibitors Revenue by Application (2021–2032)
5.2.1 Global Epidermal Growth Factor Receptor Inhibitors Revenue by Application (2021–2026)
5.2.2 Global Epidermal Growth Factor Receptor Inhibitors Revenue by Application (2027–2032)
5.2.3 Global Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Application (2021–2032)
5.3 Global Epidermal Growth Factor Receptor Inhibitors Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AstraZeneca Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Roche Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Pfizer Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Spectrum Pharmaceuticals
6.4.1 Spectrum Pharmaceuticals Company Information
6.4.2 Spectrum Pharmaceuticals Description and Business Overview
6.4.3 Spectrum Pharmaceuticals Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Spectrum Pharmaceuticals Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.4.5 Spectrum Pharmaceuticals Recent Developments/Updates
6.5 Cullinan Oncology
6.5.1 Cullinan Oncology Company Information
6.5.2 Cullinan Oncology Description and Business Overview
6.5.3 Cullinan Oncology Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Cullinan Oncology Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.5.5 Cullinan Oncology Recent Developments/Updates
6.6 Taiho Pharmaceutical
6.6.1 Taiho Pharmaceutical Company Information
6.6.2 Taiho Pharmaceutical Description and Business Overview
6.6.3 Taiho Pharmaceutical Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Taiho Pharmaceutical Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.6.5 Taiho Pharmaceutical Recent Developments/Updates
6.7 Lutris Pharma
6.7.1 Lutris Pharma Company Information
6.7.2 Lutris Pharma Description and Business Overview
6.7.3 Lutris Pharma Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Lutris Pharma Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.7.5 Lutris Pharma Recent Developments/Updates
6.8 Boehringer Ingelheim
6.8.1 Boehringer Ingelheim Company Information
6.8.2 Boehringer Ingelheim Description and Business Overview
6.8.3 Boehringer Ingelheim Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Boehringer Ingelheim Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.8.5 Boehringer Ingelheim Recent Developments/Updates
6.9 Puma Biotechnology
6.9.1 Puma Biotechnology Company Information
6.9.2 Puma Biotechnology Description and Business Overview
6.9.3 Puma Biotechnology Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Puma Biotechnology Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.9.5 Puma Biotechnology Recent Developments/Updates
6.10 Apollomics
6.10.1 Apollomics Company Information
6.10.2 Apollomics Description and Business Overview
6.10.3 Apollomics Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Apollomics Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.10.5 Apollomics Recent Developments/Updates
6.11 Hutchison MediPharma
6.11.1 Hutchison MediPharma Company Information
6.11.2 Hutchison MediPharma Description and Business Overview
6.11.3 Hutchison MediPharma Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Hutchison MediPharma Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.11.5 Hutchison MediPharma Recent Developments/Updates
6.12 Johnson & Johnson Services
6.12.1 Johnson & Johnson Services Company Information
6.12.2 Johnson & Johnson Services Description and Business Overview
6.12.3 Johnson & Johnson Services Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Johnson & Johnson Services Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.12.5 Johnson & Johnson Services Recent Developments/Updates
6.13 Daiichi Sankyo
6.13.1 Daiichi Sankyo Company Information
6.13.2 Daiichi Sankyo Description and Business Overview
6.13.3 Daiichi Sankyo Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Daiichi Sankyo Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.13.5 Daiichi Sankyo Recent Developments/Updates
6.14 Hutchison China MediTech
6.14.1 Hutchison China MediTech Company Information
6.14.2 Hutchison China MediTech Description and Business Overview
6.14.3 Hutchison China MediTech Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Hutchison China MediTech Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.14.5 Hutchison China MediTech Recent Developments/Updates
6.15 Sihuan Pharmaceutical
6.15.1 Sihuan Pharmaceutical Company Information
6.15.2 Sihuan Pharmaceutical Description and Business Overview
6.15.3 Sihuan Pharmaceutical Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Sihuan Pharmaceutical Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.15.5 Sihuan Pharmaceutical Recent Developments/Updates
6.16 Astellas Pharma
6.16.1 Astellas Pharma Company Information
6.16.2 Astellas Pharma Description and Business Overview
6.16.3 Astellas Pharma Epidermal Growth Factor Receptor Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Astellas Pharma Epidermal Growth Factor Receptor Inhibitors Product Portfolio
6.16.5 Astellas Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Epidermal Growth Factor Receptor Inhibitors Industry Chain Analysis
7.2 Epidermal Growth Factor Receptor Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Epidermal Growth Factor Receptor Inhibitors Production Mode & Process Analysis
7.4 Epidermal Growth Factor Receptor Inhibitors Sales and Marketing
7.4.1 Epidermal Growth Factor Receptor Inhibitors Sales Channels
7.4.2 Epidermal Growth Factor Receptor Inhibitors Distributors
7.5 Epidermal Growth Factor Receptor Inhibitors Customer Analysis
8 Epidermal Growth Factor Receptor Inhibitors Market Dynamics
8.1 Epidermal Growth Factor Receptor Inhibitors Industry Trends
8.2 Epidermal Growth Factor Receptor Inhibitors Market Drivers
8.3 Epidermal Growth Factor Receptor Inhibitors Market Challenges
8.4 Epidermal Growth Factor Receptor Inhibitors Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Epidermal Growth Factor Receptor Inhibitors Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Epidermal Growth Factor Receptor Inhibitors Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Epidermal Growth Factor Receptor Inhibitors Market Competitive Situation by Manufacturers in 2025
Table 4. Global Epidermal Growth Factor Receptor Inhibitors Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Epidermal Growth Factor Receptor Inhibitors Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Epidermal Growth Factor Receptor Inhibitors Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Epidermal Growth Factor Receptor Inhibitors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Epidermal Growth Factor Receptor Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Epidermal Growth Factor Receptor Inhibitors, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Epidermal Growth Factor Receptor Inhibitors, Product Types and Applications
Table 12. Global Key Manufacturers of Epidermal Growth Factor Receptor Inhibitors, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Epidermal Growth Factor Receptor Inhibitors Companies by Tier (Tier 1, Tier 2, Tier 3), based on Epidermal Growth Factor Receptor Inhibitors Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Epidermal Growth Factor Receptor Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Epidermal Growth Factor Receptor Inhibitors Sales by Region (K Units), 2021–2026
Table 18. Global Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Region (2021–2026)
Table 19. Global Epidermal Growth Factor Receptor Inhibitors Sales by Region (K Units), 2027–2032
Table 20. Global Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Region (2027–2032)
Table 21. Global Epidermal Growth Factor Receptor Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 22. Global Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Region (2021–2026)
Table 23. Global Epidermal Growth Factor Receptor Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 24. Global Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Region (2027–2032)
Table 25. North America Epidermal Growth Factor Receptor Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Epidermal Growth Factor Receptor Inhibitors Sales by Country (K Units), 2021–2026
Table 27. North America Epidermal Growth Factor Receptor Inhibitors Sales by Country (K Units), 2027–2032
Table 28. North America Epidermal Growth Factor Receptor Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 29. North America Epidermal Growth Factor Receptor Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Epidermal Growth Factor Receptor Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Epidermal Growth Factor Receptor Inhibitors Sales by Country (K Units), 2021–2026
Table 32. Europe Epidermal Growth Factor Receptor Inhibitors Sales by Country (K Units), 2027–2032
Table 33. Europe Epidermal Growth Factor Receptor Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Epidermal Growth Factor Receptor Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Epidermal Growth Factor Receptor Inhibitors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Epidermal Growth Factor Receptor Inhibitors Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Epidermal Growth Factor Receptor Inhibitors Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Epidermal Growth Factor Receptor Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Epidermal Growth Factor Receptor Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Epidermal Growth Factor Receptor Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Epidermal Growth Factor Receptor Inhibitors Sales by Country (K Units), 2021–2026
Table 42. Latin America Epidermal Growth Factor Receptor Inhibitors Sales by Country (K Units), 2027–2032
Table 43. Latin America Epidermal Growth Factor Receptor Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Epidermal Growth Factor Receptor Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 50. Global Epidermal Growth Factor Receptor Inhibitors Sales (K Units) by Type (2021–2026)
Table 51. Global Epidermal Growth Factor Receptor Inhibitors Sales (K Units) by Type (2027–2032)
Table 52. Global Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Type (2021–2026)
Table 53. Global Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Type (2027–2032)
Table 54. Global Epidermal Growth Factor Receptor Inhibitors Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Epidermal Growth Factor Receptor Inhibitors Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Type (2021–2026)
Table 57. Global Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Type (2027–2032)
Table 58. Global Epidermal Growth Factor Receptor Inhibitors Price (US$/Unit) by Type (2021–2026)
Table 59. Global Epidermal Growth Factor Receptor Inhibitors Price (US$/Unit) by Type (2027–2032)
Table 60. Global Epidermal Growth Factor Receptor Inhibitors Sales (K Units) by Application (2021–2026)
Table 61. Global Epidermal Growth Factor Receptor Inhibitors Sales (K Units) by Application (2027–2032)
Table 62. Global Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Application (2021–2026)
Table 63. Global Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Application (2027–2032)
Table 64. Global Epidermal Growth Factor Receptor Inhibitors Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Epidermal Growth Factor Receptor Inhibitors Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Application (2021–2026)
Table 67. Global Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Application (2027–2032)
Table 68. Global Epidermal Growth Factor Receptor Inhibitors Price (US$/Unit) by Application (2021–2026)
Table 69. Global Epidermal Growth Factor Receptor Inhibitors Price (US$/Unit) by Application (2027–2032)
Table 70. AstraZeneca Company Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. AstraZeneca Epidermal Growth Factor Receptor Inhibitors Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Roche Company Information
Table 76. Roche Description and Business Overview
Table 77. Roche Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Roche Epidermal Growth Factor Receptor Inhibitors Product
Table 79. Roche Recent Developments/Updates
Table 80. Pfizer Company Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Pfizer Epidermal Growth Factor Receptor Inhibitors Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Spectrum Pharmaceuticals Company Information
Table 86. Spectrum Pharmaceuticals Description and Business Overview
Table 87. Spectrum Pharmaceuticals Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Spectrum Pharmaceuticals Epidermal Growth Factor Receptor Inhibitors Product
Table 89. Spectrum Pharmaceuticals Recent Developments/Updates
Table 90. Cullinan Oncology Company Information
Table 91. Cullinan Oncology Description and Business Overview
Table 92. Cullinan Oncology Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Cullinan Oncology Epidermal Growth Factor Receptor Inhibitors Product
Table 94. Cullinan Oncology Recent Developments/Updates
Table 95. Taiho Pharmaceutical Company Information
Table 96. Taiho Pharmaceutical Description and Business Overview
Table 97. Taiho Pharmaceutical Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Taiho Pharmaceutical Epidermal Growth Factor Receptor Inhibitors Product
Table 99. Taiho Pharmaceutical Recent Developments/Updates
Table 100. Lutris Pharma Company Information
Table 101. Lutris Pharma Description and Business Overview
Table 102. Lutris Pharma Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Lutris Pharma Epidermal Growth Factor Receptor Inhibitors Product
Table 104. Lutris Pharma Recent Developments/Updates
Table 105. Boehringer Ingelheim Company Information
Table 106. Boehringer Ingelheim Description and Business Overview
Table 107. Boehringer Ingelheim Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Boehringer Ingelheim Epidermal Growth Factor Receptor Inhibitors Product
Table 109. Boehringer Ingelheim Recent Developments/Updates
Table 110. Puma Biotechnology Company Information
Table 111. Puma Biotechnology Description and Business Overview
Table 112. Puma Biotechnology Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Puma Biotechnology Epidermal Growth Factor Receptor Inhibitors Product
Table 114. Puma Biotechnology Recent Developments/Updates
Table 115. Apollomics Company Information
Table 116. Apollomics Description and Business Overview
Table 117. Apollomics Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Apollomics Epidermal Growth Factor Receptor Inhibitors Product
Table 119. Apollomics Recent Developments/Updates
Table 120. Hutchison MediPharma Company Information
Table 121. Hutchison MediPharma Description and Business Overview
Table 122. Hutchison MediPharma Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Hutchison MediPharma Epidermal Growth Factor Receptor Inhibitors Product
Table 124. Hutchison MediPharma Recent Developments/Updates
Table 125. Johnson & Johnson Services Company Information
Table 126. Johnson & Johnson Services Description and Business Overview
Table 127. Johnson & Johnson Services Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Johnson & Johnson Services Epidermal Growth Factor Receptor Inhibitors Product
Table 129. Johnson & Johnson Services Recent Developments/Updates
Table 130. Daiichi Sankyo Company Information
Table 131. Daiichi Sankyo Description and Business Overview
Table 132. Daiichi Sankyo Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Daiichi Sankyo Epidermal Growth Factor Receptor Inhibitors Product
Table 134. Daiichi Sankyo Recent Developments/Updates
Table 135. Hutchison China MediTech Company Information
Table 136. Hutchison China MediTech Description and Business Overview
Table 137. Hutchison China MediTech Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Hutchison China MediTech Epidermal Growth Factor Receptor Inhibitors Product
Table 139. Hutchison China MediTech Recent Developments/Updates
Table 140. Sihuan Pharmaceutical Company Information
Table 141. Sihuan Pharmaceutical Description and Business Overview
Table 142. Sihuan Pharmaceutical Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Sihuan Pharmaceutical Epidermal Growth Factor Receptor Inhibitors Product
Table 144. Sihuan Pharmaceutical Recent Developments/Updates
Table 145. Astellas Pharma Company Information
Table 146. Astellas Pharma Description and Business Overview
Table 147. Astellas Pharma Epidermal Growth Factor Receptor Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Astellas Pharma Epidermal Growth Factor Receptor Inhibitors Product
Table 149. Astellas Pharma Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Epidermal Growth Factor Receptor Inhibitors Distributors List
Table 153. Epidermal Growth Factor Receptor Inhibitors Customers List
Table 154. Epidermal Growth Factor Receptor Inhibitors Market Trends
Table 155. Epidermal Growth Factor Receptor Inhibitors Market Drivers
Table 156. Epidermal Growth Factor Receptor Inhibitors Market Challenges
Table 157. Epidermal Growth Factor Receptor Inhibitors Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
Table 161. Authors List of This Report
List of Figures
Figure 1. Product Picture of Epidermal Growth Factor Receptor Inhibitors
Figure 2. Global Epidermal Growth Factor Receptor Inhibitors Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Epidermal Growth Factor Receptor Inhibitors Market Share by Type: 2025 & 2032
Figure 4. Cetuximab Product Picture
Figure 5. Erlotinib Product Picture
Figure 6. Gefitinib Product Picture
Figure 7. Other Product Picture
Figure 8. Global Epidermal Growth Factor Receptor Inhibitors Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Epidermal Growth Factor Receptor Inhibitors Market Share by Application: 2025 & 2032
Figure 10. Lung Cancer
Figure 11. Liver Cancer
Figure 12. Breast Cancer
Figure 13. Other
Figure 14. Global Epidermal Growth Factor Receptor Inhibitors Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Epidermal Growth Factor Receptor Inhibitors Market Size (US$ Million), 2021–2032
Figure 16. Global Epidermal Growth Factor Receptor Inhibitors Sales (K Units), 2021–2032
Figure 17. Global Epidermal Growth Factor Receptor Inhibitors Average Price (US$/Unit), 2021–2032
Figure 18. Epidermal Growth Factor Receptor Inhibitors Report Years Considered
Figure 19. Epidermal Growth Factor Receptor Inhibitors Sales Share by Manufacturers in 2025
Figure 20. Global Epidermal Growth Factor Receptor Inhibitors Revenue Share by Manufacturers in 2025
Figure 21. Top 5 and Top 10 Global Epidermal Growth Factor Receptor Inhibitors Players: Market Share by Revenue in Epidermal Growth Factor Receptor Inhibitors in 2025
Figure 22. Epidermal Growth Factor Receptor Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 23. Global Epidermal Growth Factor Receptor Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 24. North America Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Country (2021–2032)
Figure 25. North America Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Country (2021–2032)
Figure 26. United States Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Canada Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Europe Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Country (2021–2032)
Figure 29. Europe Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Country (2021–2032)
Figure 30. Germany Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. France Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. U.K. Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Italy Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Russia Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Asia Pacific Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Region (2021–2032)
Figure 36. Asia Pacific Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Region (2021–2032)
Figure 37. China Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Japan Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. South Korea Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. India Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Australia Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. China Taiwan Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Southeast Asia Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Latin America Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Country (2021–2032)
Figure 45. Latin America Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Country (2021–2032)
Figure 46. Mexico Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Brazil Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Argentina Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Colombia Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Sales Market Share by Country (2021–2032)
Figure 51. Middle East and Africa Epidermal Growth Factor Receptor Inhibitors Revenue Market Share by Country (2021–2032)
Figure 52. Turkey Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Saudi Arabia Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. UAE Epidermal Growth Factor Receptor Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Global Sales Market Share of Epidermal Growth Factor Receptor Inhibitors by Type (2021–2032)
Figure 56. Global Revenue Market Share of Epidermal Growth Factor Receptor Inhibitors by Type (2021–2032)
Figure 57. Global Epidermal Growth Factor Receptor Inhibitors Price (US$/Unit) by Type (2021–2032)
Figure 58. Global Sales Market Share of Epidermal Growth Factor Receptor Inhibitors by Application (2021–2032)
Figure 59. Global Revenue Market Share of Epidermal Growth Factor Receptor Inhibitors by Application (2021–2032)
Figure 60. Global Epidermal Growth Factor Receptor Inhibitors Price (US$/Unit) by Application (2021–2032)
Figure 61. Epidermal Growth Factor Receptor Inhibitors Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
